Format

Send to

Choose Destination
Acta Neurochir (Wien). 2017 Nov;159(11):2217-2221. doi: 10.1007/s00701-017-3311-0. Epub 2017 Sep 16.

Recurrent papillary craniopharyngioma with BRAFV600E mutation treated with neoadjuvant-targeted therapy.

Author information

1
Section of Neurosurgery, Department of Neuroscience, Uppsala University, SE-751 85, Uppsala, Sweden. Elham.rostami@neuro.uu.se.
2
Department of Immunology, Genetics and Pathology, Clinical and experimental Oncology, Uppsala University, Uppsala, Sweden.
3
Skandionkliniken, Uppsala, Sweden.
4
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
5
Department of Clinical Pathology, Uppsala University Hospital, Uppsala, Sweden.
6
Department of Radiology, Uppsala University, Uppsala, Sweden.
7
Section of Neurosurgery, Department of Neuroscience, Uppsala University, SE-751 85, Uppsala, Sweden.

Abstract

Craniopharyngiomas are histologically benign but locally aggressive tumors in the sellar region that may cause devastating neurological and endocrine deficits. They tend to recur following surgery with high morbidity; hence, postoperative radiotherapy is recommended following sub-total resection. BRAFV600E mutation is the principal oncogenic driver in the papillary variant of craniopharyngiomas. Recently, a dramatic tumor reduction has been reported in a patient with BRAFV600E mutated, multiply recurrent papillary craniopharyngioma using a combination therapy of BRAF inhibitor dabrafenib and MEK inhibitor trametinib. Here, we report on near-radical reduction of a growing residual BRAFV600E craniopharyngioma using the same neoadjuvant therapy.

KEYWORDS:

BRAFV600E; Craniopharyngioma; RAF-inhibitor

PMID:
28918496
PMCID:
PMC5636852
DOI:
10.1007/s00701-017-3311-0
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center